Desmond Chee
0000-0003-3473-9447
4 papers found
Refreshing results…
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.
Missing publications? Search for publications with a matching author name.